Text version
Finally, in this volume of Quick Takes, here’s a quick look at an adjunctive treatment in schizophrenia.
In the United States, there is something that’s been dubbed to be “a recovery movement,” which emphasizes improvement in function and making that potentially even more important than reducing psychotic symptoms, like auditory hallucinations. And in that light, here’s a new study of ondansetron targeting cognitive function. There were some previous studies that suggest that ondansetron, which is a 5-HT3 antagonist originally developed for nausea, but it has some dopamine antagonism as well, might be of some benefit even in reducing psychosis and possibly a mild benefit on reducing AIMS scores (the Abnormal Involuntary Movement Scale). And then there were a couple of studies looking at the PANSS (the Positive and Negative Symptom Scale) as a kind of a big-picture indicator of how much improvement one is seeing in schizophrenia.
In this new
Unlock this Quick Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.
Already have an account? Sign in
